Imago BioSciences Appoints Matthew J. Plunkett as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif.–(Small business WIRE)–Jan 19, 2021–

Imago BioSciences, Inc. (Imago), a clinical phase biopharmaceutical corporation acquiring ground breaking treatments for myeloid ailments, today declared the appointment of Matthew J. Plunkett, Ph.D., as main monetary officer (CFO). Plunkett will guide the company’s business enterprise and financial functions.

“Matt has a tested track file of steering both equally non-public and community everyday living sciences corporations to significant milestones,” reported Hugh Young Rienhoff, Jr. M.D., chief government officer, Imago BioSciences. “His deep fiscal acumen, scientific education and sturdy money markets track record will serve us properly as we construct Imago. We are thrilled to have Matt as section of the Imago group as we advance our medical enhancement in myeloid condition.”

Dr. Plunkett has invested the very last two a long time as a biopharma investment decision banker and senior biotechnology government. Dr. Plunkett joins Imago from Nkarta Therapeutics, Inc., where he was main fiscal officer from 2018 to 2020. Beforehand, he was chief fiscal and enterprise officer at Medeor Therapeutics from 2017 to 2018. Prior to that, he served as a small business progress government at CTI BioPharma from 2012 right up until 2017, together with as chief business enterprise officer from 2014 to 2017. From 2000 to 2009, Matt held positions of growing responsibility in the healthcare expenditure banking division of CIBC Earth Marketplaces and its U.S. successor Oppenheimer & Co., culminating in leadership of the west coastline biotech investment banking follow. Dr. Plunkett began his specialist vocation as a bench scientist in combinatorial chemistry. He attained a B.S. in chemistry from Harvey Mudd College or university and a Ph.D. in natural chemistry from the College of California, Berkeley.

“I’m psyched to join Imago at these a pivotal time,” said Dr. Matthew Plunkett, chief monetary officer, Imago BioSciences. “Imago not long ago closed on an $80 million Series C financing, and with info from more than 100 people dealt with to day with bomedemstat, we are poised to go into late-stage clinical trials and address the major unmet need to have for folks with myeloproliferative problems. Our investigational therapies have the opportunity to be actually sickness modifying. I am honored to join the Imago group and lead to our mission of bringing these novel therapies to people.”

About Bomedemstat (IMG-7289)
Bomedemstat is an orally obtainable modest molecule identified and produced by Imago BioSciences that inhibits lysine-precise demethylase 1 (LSD1 or KDM1A), an enzyme revealed to be vital in most cancers stem/progenitor cells, specially neoplastic bone marrow cells. In non-clinical experiments, bomedemstat demonstrated robust in vivo anti-tumor efficacy throughout a assortment of myeloid malignancies as a one agent and in mixture with other therapeutic brokers. Bomedemstat is an investigational agent now becoming evaluated in ongoing medical trials ( Identifier: NCT03136185, NCT04262141, NCT04254978 and NCT04081220 ).

Bomedemstat has U.S. Fda Orphan Drug and Speedy Keep track of Designation for the remedy of myelofibrosis and important thrombocythemia, Orphan Drug Designation for procedure of acute myeloid leukemia and Prime designation by the European Medicines Company for the therapy of MF.

Bomedemstat is currently being evaluated in three open up-label Period 2 scientific trials for the remedy of state-of-the-art myelofibrosis (MF), polycythemia vera (PV) and important thrombocythemia (ET), bone marrow cancers that interfere with the creation of blood cells. MF clients who are resistant to a Janus Kinase (JAK) inhibitor and ET patients who have failed a person standard of treatment therapy are eligible for the bomedemstat MF and ET studies, respectively.

About Imago BioSciences
Imago BioSciences is a medical-phase biopharmaceutical enterprise concentrated on exploring and building novel therapeutics for the treatment method of hematologic conditions. Imago has made a sequence of compounds that inhibit LSD1, an epigenetic enzyme essential for cancer stem cell function and blood mobile differentiation. The enterprise is advancing the medical enhancement of its first LSD1 inhibitor, bomedemstat, for the remedy of myeloid neoplasms. Imago is backed by primary non-public, general public and strategic investors together with a fund managed by Blackstone Lifetime Sciences, Frazier Health care Companions, Omega Money, Farallon Money Management, L.L.C., money and accounts advised by T. Rowe Price Associates, Inc., and resources and accounts managed by Blackrock Advisors, LLC. The business is based in South San Francisco, California. To discover much more, stop by,, and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

Look at source edition on

Contact: Media Get hold of:

Steve Kunszabo

Canale Communications

[email protected]

Trader Call:

Matthew Plunkett, PhD,

Chief Fiscal Officer, Imago Biosciences

[email protected]



Source: Imago BioSciences, Inc.

Copyright Company Wire 2021.

PUB: 01/19/2021 08:00 AM/DISC: 01/19/2021 08:01 AM